Hematology | Clinical

Debating the Significance of MRD in Blood Cancers vs Initial Patient Characteristics

September 28, 2022

In the myeloma space, minimal residual disease negativity is prognostic of progression-free survival in relapsed or refractory patients. In leukemia, the biomarker combined with other prognostication techniques provides complex information that is clinically relevant.

BPDCN: Epidemiology, Pathophysiology, and Diagnosis

September 27, 2022

Opening the discussion on the management of BPDCN, an expert panel consisting of two hematologist-oncologists and a pathologist, considers the causes, incidence and diagnostic approach to this rare disease.

FDA Approves Eflapegrastim for Chemotherapy-Induced Neutropenia

September 09, 2022

The FDA has approved eflapegrastim-xnst injection for adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs linked with clinically significant incidence of febrile neutropenia.